Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 9.16 USD -3.17% Market Closed
Market Cap: 948.2m USD

Intrinsic Value

NTLA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NTLA stock under the Base Case scenario is 22.17 USD. Compared to the current market price of 9.16 USD, Intellia Therapeutics Inc is Undervalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NTLA Intrinsic Value
22.17 USD
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Intellia Therapeutics Inc

Valuation History Unavailable

Historical valuation for NTLA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Intellia Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Intellia Therapeutics Inc

Current Assets 551.4m
Cash & Short-Term Investments 503.7m
Receivables 10.5m
Other Current Assets 37.1m
Non-Current Assets 434.8m
Long-Term Investments 228.1m
PP&E 163.1m
Other Non-Current Assets 43.6m
Efficiency

Free Cash Flow Analysis
Intellia Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Intellia Therapeutics Inc

Revenue
45.6m USD
Operating Expenses
-586.6m USD
Operating Income
-541.1m USD
Other Expenses
15.2m USD
Net Income
-525.9m USD
Fundamental Scores

NTLA Profitability Score
Profitability Due Diligence

Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
Declining ROE
23/100
Profitability
Score

Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

NTLA Solvency Score
Solvency Due Diligence

Intellia Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Intellia Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 42.5 USD with a low forecast of 8.08 USD and a high forecast of 111.3 USD.

Lowest
Price Target
8.08 USD
12% Downside
Average
Price Target
42.5 USD
364% Upside
Highest
Price Target
111.3 USD
1 115% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Intellia Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NTLA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NTLA Insider Trading
Buy and sell transactions by insiders

NTLA News

Other Videos
What is the Intrinsic Value of one NTLA stock?

The intrinsic value of one NTLA stock under the Base Case scenario is 22.17 USD.

Is NTLA stock undervalued or overvalued?

Compared to the current market price of 9.16 USD, Intellia Therapeutics Inc is Undervalued by 59%.

Back to Top